Cargando…

Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?

PURPOSE: This review aims to provide an overview of the impact of TNFis biosimilars, with marketing authorization, in patient-reported outcome measures (PROMs) scores and explore how PROMs endpoints might add value in biosimilars uptake in RA patients. PATIENTS AND METHODS: A comprehensive search of...

Descripción completa

Detalles Bibliográficos
Autor principal:	Horta-Baas, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977480/ https://www.ncbi.nlm.nih.gov/pubmed/35388274 http://dx.doi.org/10.2147/PROM.S256715

Ejemplares similares

Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea
por: Cho, Soo-Kyung, et al.
Publicado: (2021)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Biosimilars: Key regulatory considerations and similarity assessment tools
por: Kirchhoff, Carol F., et al.
Publicado: (2017)

Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between Gut Microbiota and the Pathogenesis of Rheumatoid Arthritis
por: Horta-Baas, Gabriel, et al.
Publicado: (2017)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
por: Cohen, Stanley B, et al.
Publicado: (2023)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
por: Bonek, Krzysztof, et al.
Publicado: (2021)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
por: Wells, Alvin F, et al.
Publicado: (2014)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

Total Knee Arthroplasty Considerations in Rheumatoid Arthritis
por: Danoff, Jonathan R., et al.
Publicado: (2013)

Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
por: Lai, Zhihong, et al.
Publicado: (2016)

Pharmacovigilance Considerations for Biosimilars in the USA
por: Grampp, Gustavo, et al.
Publicado: (2015)

Clinical considerations for biosimilar antibodies
por: Mellstedt, Håkan
Publicado: (2013)

Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval
por: Strauss, David G., et al.
Publicado: (2022)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis
por: Kay, Jonathan, et al.
Publicado: (2022)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
por: Waller, John, et al.
Publicado: (2017)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015)

The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review
por: Taylor, Peter C., et al.
Publicado: (2021)

Gut-joint axis: Gut dysbiosis can contribute to the onset of rheumatoid arthritis via multiple pathways
por: Romero-Figueroa, María del Socorro, et al.
Publicado: (2023)

Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations
por: Ajeganova, Sofia, et al.
Publicado: (2017)

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13
por: Sakane, Hideo, et al.
Publicado: (2022)

Current status and considerations on biosimilar in China
por: Wang, Junzhi
Publicado: (2012)

Management of rheumatoid arthritis in People’s Republic of China – focus on tocilizumab and patient considerations
por: Wang, Geng, et al.
Publicado: (2015)

Drug tendering: drug supply and shortage implications for the uptake of biosimilars
por: Dranitsaris, George, et al.
Publicado: (2017)

The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
por: Talotta, Rossella, et al.
Publicado: (2017)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Policies for biosimilar uptake in Europe: An overview
por: Moorkens, Evelien, et al.
Publicado: (2017)

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis
por: Smolen, Josef S., et al.
Publicado: (2020)

Practical Considerations for Integrating Biosimilars Into Clinical Practice
por: May, Megan B., et al.
Publicado: (2021)

Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use
por: Hazes, Johanna M.W., et al.
Publicado: (2011)

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
por: Scheinberg, Morton, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ogjn01fkbkm3r6ep3hqfdocj59